Literature DB >> 11857311

Stromelysin-3 is expressed by aggressive meningiomas.

Anne Gentil Perret1, Robert Duthel, Marie-Jeanette Fotso, Jacques Brunon, Jean-François Mosnier.   

Abstract

BACKGROUND: Stromelysin-3 (ST3) that belongs to the metalloproteinase family is proposed to play a role in tumor invasion. The purpose of this work was to study the variation of ST3 expression in meningiomas.
METHODS: Twenty atypical meningiomas were retrieved from the Pathology Department's files at Hopital de Bellevue, Saint-Etienne, France. They were compared with 20 benign meningiomas randomly selected from the same file. The tumors were classified using standard histologic criteria. Frozen sections of the tumors were immunostained for ST3 and MIB-1 to evaluate the proliferative activity of tumor cells.
RESULTS: The study included 5 fibrous meningiomas, 10 transitional meningiomas, 20 syncitial meningiomas, 2 secretory meningiomas, 2 microcystic meningiomas, and 1 angiomatous meningioma. Stromelysin-3 was expressed within the stromal and neoplastic cells of only 1 benign meningioma and 13 atypical meningiomas. The MIB-1 proliferation index was significantly higher in the meningiomas expressing ST3 (Student t test: P < 0.001). The invasion of bone, muscle, and brain by meningiomas as well the recurrence were statistically correlated with their ST3 expression (Kruskal-Wallis nonparametric correlation test, P = 0.001 and P = 0.008, respectively).
CONCLUSIONS: Stromelysin-3 might play an important role in the invasiveness of meningiomas. Therefore, considering, ST3 in association with evaluation of the MIB-1 proliferating index may be an useful tool to assess the behavior of meningiomas. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10270

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857311     DOI: 10.1002/cncr.10270

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

2.  Possible role of matrix metalloproteinase in osteolytic intracranial meningiomas.

Authors:  Hyung-Sik Moon; Shin Jung; Tae-Young Jung; Van Thang Cao; Kyung-Sub Moon; In-Young Kim
Journal:  J Korean Neurosurg Soc       Date:  2010-01-31

3.  Matrix Metalloproteinase 11 is a Potential Biomarker in Bladder Cancer Diagnosis and Prognosis.

Authors:  Chen Chen; Xiaoping Liu; Jiazhi Jiang; Shenjuan Li; Gang Wang; Lingao Ju; Fubing Wang; Tongzu Liu; Sheng Li
Journal:  Onco Targets Ther       Date:  2020-09-11       Impact factor: 4.147

4.  Secretory meningiomas: a benign subgroup causing life-threatening complications.

Authors:  Jan Regelsberger; Christian Hagel; Pedram Emami; Thorsten Ries; Oliver Heese; Manfred Westphal
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Antigen expression on recurrent meningioma cells.

Authors:  Andrej Vranic
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

Review 6.  Molecular neuropathology of brain-invasive meningiomas.

Authors:  Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

7.  Impact of Matrix Metalloproteinases 11 Gene Variants on Urothelial Cell Carcinoma Development and Clinical Characteristics.

Authors:  Chien-Chang Li; Ming-Ju Hsieh; Shian-Shiang Wang; Sheng-Chun Hung; Chia-Yen Lin; Chi-Wen Kuo; Shun-Fa Yang; Ying-Erh Chou
Journal:  Int J Environ Res Public Health       Date:  2020-01-11       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.